非布司他治疗痛风的疗效怎样呢？

Febuxostat (Febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor approved for marketing. It can reduce blood urate concentration and is currently a new drug in the treatment of gout. Because of its remarkable efficacy and safety, it has been widely used in clinical research.

Several guidelines have recommended the use of febuxostat for the treatment of gout. The "British Society of Rheumatology Guidelines for the Diagnosis and Treatment of Gout (2017)" recommends allopurinol as the first-line uric acid-lowering drug. If allopurinol cannot be tolerated or the dose of allopurinol cannot be increased due to renal function to a level sufficient to achieve the serum uric acid target, febuxostat can be selected. The starting dose of febuxostat is 80 mg/d, which can be increased to 120 mg/d after 4 weeks if necessary to achieve treatment goals.

The safety and efficacy of febuxostat (febuxostat) in gout were evaluated based on a multicenter, double-blind, randomized phase II clinical study. A total of 136 men and 17 women with gout were randomized to receive placebo or febuxostat (40, 80, or 120 mg/day).

After 4 weeks, the test found that the serum uric acid concentration of patients in each dose group of febuxostat was significantly lower than before treatment. According to the dose, each group decreased by an average of 37%, 44% and 59% respectively, while the patients in the placebo group only decreased by 2%.

The vast majority of patients persisted in completing the trial. The incidence of adverse reactions in the febuxostat (Febuxostat) and placebo groups was similar, and most of these adverse reactions were mild and self-limiting. Common ones included diarrhea, pain, back pain, headache, and joint pain.

The "Chinese Gout Diagnosis and Treatment Guidelines (2016)" recommends that gout patients can use allopurinol (2B) or febuxostat (febuxostat) (2B) to inhibit uric acid production, but febuxostat has more advantages than allopurinol in terms of effectiveness and safety. The uric acid-lowering effect of febuxostat 40 mg/day is similar to that of allopurinol 300 mg/day.